Invention Grant
- Patent Title: Sustained release oral dosage form containing dalfampridine
-
Application No.: US15256636Application Date: 2016-09-05
-
Publication No.: US10172842B2Publication Date: 2019-01-08
- Inventor: Chih-Yao Yang , Jen-Sen Wu , Shih-Wei Huang , Yi-Chen Tsai , Chieh-Wen Chang , Cheng-Wei Chang
- Applicant: PharmaDax Inc.
- Applicant Address: TW New Taipei
- Assignee: PharmaDax Inc.
- Current Assignee: PharmaDax Inc.
- Current Assignee Address: TW New Taipei
- Agency: CKC & Partners Co., Ltd.
- Main IPC: A61K31/4409
- IPC: A61K31/4409 ; A61K9/00 ; A61K9/20 ; A61K9/28

Abstract:
The present invention provides a sustained release oral dosage form containing dalfampridine that can be administered once daily. The dosage form includes dalfampridine as the active pharmaceutical ingredient and the excipients comprising osmotic agents in a tablet core. The sustained release oral dosage form of the present invention can be administrated once daily and can provide a proper fluctuation index to reduce undesired adverse effect, prevent alcohol-induced dose dumping and release drug at a rate sufficient to maintain certain drug plasma concentration.
Public/Granted literature
- US20170071923A1 SUSTAINED RELEASE ORAL DOSAGE FORM CONTAINING DALFAMPRIDINE Public/Granted day:2017-03-16
Information query
IPC分类: